Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 55
Filtrar
1.
Jpn J Infect Dis ; 54(5): 184-8, 2001 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-11754156

RESUMEN

Kawaura, a rural town in Kumamoto Prefecture, Japan, population approximately 6,800, started a mass influenza vaccination campaign in the 1999-2000 season for all residents > or = 3 years of age. The town provided free vaccinations to children < or = 13 years and the elderly > or = 65 years. Only 900 yen (US$8.80) was charged to the other residents for two vaccinations. In the 1999-2000 season, a total of 5,563 doses of vaccine were administered to 2,952 residents. Over 90% of the vaccinees received two doses. The program resulted in a vaccination rate of 43% of all residents. The vaccination rates for females and males were 40.7% and 36.8%, and for those of 3-14 years, 15-64 years, and > or = 65 years population were 75%, 31%, and 55%, respectively. The town spent a total of 5.78 million yen (US$56,700) for the campaign. The per-shot cost was estimated as 1,683 yen (US$16.50). From December 1999 through March 2000, a total of 233 town residents (15-101 years old, median 72) were admitted to the town hospital. Of the 233 inpatients, 22 (66-98 years old, median 78) developed respiratory illness, with 4 fatal outcomes. Of these 22 cases, 3 had been vaccinated twice, while 19 had not been vaccinated at all. The relative risk of vaccinees' hospitalization due to respiratory illness decreased to 0.13 compared with that of non-vaccinees (3/1,203 versus 19/1,003, vaccine efficacy = 0.87). Likewise, the relative risk of vaccinees death due to respiratory illness decreased to 0.28 compared with that of non-vaccinees (1/1,203 versus 3/1,003). The results of the Kawaura town's initiative should be helpful for better modeling of mass influenza vaccination campaigns.


Asunto(s)
Programas de Inmunización , Virus de la Influenza A/inmunología , Vacunas contra la Influenza/administración & dosificación , Gripe Humana/prevención & control , Adolescente , Adulto , Anciano , Niño , Preescolar , Femenino , Humanos , Esquemas de Inmunización , Gripe Humana/epidemiología , Japón/epidemiología , Masculino , Persona de Mediana Edad , Resultado del Tratamiento , Vacunación/economía
2.
Clin Infect Dis ; 28 Suppl 1: S14-20, 1999 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-10028106

RESUMEN

Since the 1993 treatment guidelines for sexually transmitted diseases were published by the Centers for Disease Control and Prevention, experience has indicated that the regimens recommended then remain largely effective. The recommended therapies--with azithromycin (1 g orally, once), ceftriaxone (250 mg intramuscularly, once), or erythromycin (500 mg orally, four times a day for 7 days)--appear highly effective in the United States; limited data from Kenya suggest that the ceftriaxone regimen may not be as effective there as it once was. The alternative regimen of ciprofloxacin proposed in 1993 (500 mg orally, twice a day for 3 days) is as effective as the recommended therapies, but new information indicates that single-dose therapy with 500 mg orally is not as effective as the use of either larger single doses or more prolonged therapy. Persons who are infected with human immunodeficiency virus (HIV) do not respond as well as those who are not HIV-infected, and males who are uncircumcised appear not to respond as well as those who are circumcised.


Asunto(s)
Chancroide/tratamiento farmacológico , Humanos
3.
Clin Infect Dis ; 28 Suppl 1: S57-65, 1999 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-10028110

RESUMEN

We reviewed data on the treatment of bacterial vaginosis published from 1993 through 1996. For nonpregnant women, we recommend use of metronidazole (500 mg orally twice daily for 7 days), clindamycin vaginal cream (2%, once daily for 7 days), or metronidazole vaginal gel (0.75%, twice daily for 5 days) as the preferred treatment for bacterial vaginosis. For pregnant high-risk women (women with a prior preterm birth), the objective of the treatment is to prevent adverse outcomes of pregnancy, in addition to relief of symptoms. Thus, systemic therapy for possible subclinical upper tract infection as well as medication that has been studied in pregnant women are preferable. Therefore, we recommend metronidazole (250 mg orally three times a day for 7 days). For pregnant low-risk women (women without a prior preterm birth) with symptomatic disease, the main objective of the treatment is to relieve symptoms. We recommend metronidazole (250 mg orally three times a day for 7 days). Data do not support routine treatment of male sex partners.


Asunto(s)
Vaginosis Bacteriana/tratamiento farmacológico , Femenino , Humanos , Masculino , Embarazo
5.
Infect Dis Obstet Gynecol ; 6(3): 134-7, 1998.
Artículo en Inglés | MEDLINE | ID: mdl-9785110

RESUMEN

BACKGROUND: Although congenital syphilis usually occurs as a result of a failure to detect and treat syphilis in pregnant women, failures of the currently recommended regimen to prevent congenital syphilis have been reported. CASE: This report describes an infant with congenital syphilis despite maternal treatment with a regimen exceeding current CDC guidelines. CONCLUSION: Regardless of the regimen used to treat syphilis during pregnancy, clinicians should recognize the possibility of occasional treatment failures and the importance of adequate follow-up of infants at risk for congenital syphilis.


Asunto(s)
Antibacterianos/administración & dosificación , Penicilinas/administración & dosificación , Complicaciones Infecciosas del Embarazo/tratamiento farmacológico , Sífilis Congénita/diagnóstico , Sífilis Congénita/etiología , Sífilis Latente/tratamiento farmacológico , Adulto , Centers for Disease Control and Prevention, U.S. , Diagnóstico Diferencial , Femenino , Humanos , Recién Nacido , Guías de Práctica Clínica como Asunto , Embarazo , Sífilis Latente/complicaciones , Insuficiencia del Tratamiento , Estados Unidos
6.
Emerg Infect Dis ; 3(2): 83-94, 1997.
Artículo en Inglés | MEDLINE | ID: mdl-9204289

RESUMEN

Understanding and quantifying the impact of a bioterrorist attack are essential in developing public health preparedness for such an attack. We constructed a model that compares the impact of three classic agents of biologic warfare (Bacillus anthracis, Brucella melitensis, and Francisella tularensis) when released as aerosols in the suburb of a major city. The model shows that the economic impact of a bioterrorist attack can range from an estimated $477.7 million per 100,000 persons exposed (brucellosis scenario) to $26.2 billion per 100,000 persons exposed (anthrax scenario). Rapid implementation of a postattack prophylaxis program is the single most important means of reducing these losses. By using an insurance analogy, our model provides economic justification for preparedness measures.


Asunto(s)
Carbunco/economía , Guerra Biológica , Brucella melitensis , Brucelosis/economía , Tularemia/economía , Carbunco/prevención & control , Brucelosis/prevención & control , Costos de la Atención en Salud , Hospitalización/economía , Humanos , Tularemia/prevención & control
8.
Sex Transm Dis ; 23(1): 45-50, 1996.
Artículo en Inglés | MEDLINE | ID: mdl-8801642

RESUMEN

Serologic testing for syphilis is a cornerstone of syphilis control efforts, but our objectives for doing it and the costs involved are not always recognized. Tests applied to individuals with symptoms or signs may be viewed as diagnostic tests, and tests applied to individuals with no clinical indications for testing may be viewed as screening tests. Infected individuals whom we detect through screening efforts are important, mostly from an individual and economic standpoint, because treatment will prevent the late complications of syphilis and thus avoid high medical costs. Because they are uncommonly infectious for others, however, they are relatively unimportant from a public health intervention standpoint. The prevalence of infection above which we should screen is based mostly on economic grounds, but is undetermined. We intuitively recognize such a threshold, however, when we use epidemiologic markers to restrict our efforts to groups in whom we think the yield is worth the effort (i.e., targeted [focused] screening). In deciding whether to institute or increase screening efforts for syphilis, we must consider not only the dollar costs of these efforts, but also the opportunity costs (i.e., what programs we will forgo so that we can devote our resources to the increased efforts). Similarly, because syphilis is not the only priority with which governments, health departments, and sexually transmitted disease programs must contend, any broader plan to significantly enhance syphilis control must acknowledge this reality and show the benefit, economic and otherwise, of its adoption.


Asunto(s)
Tamizaje Masivo , Sífilis/prevención & control , Análisis Costo-Beneficio , Femenino , Recursos en Salud , Humanos , Tamizaje Masivo/economía , Tamizaje Masivo/estadística & datos numéricos , Embarazo , Prevalencia , Pruebas Serológicas , Sífilis/epidemiología
9.
J Clin Microbiol ; 33(12): 3257-9, 1995 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-8586712

RESUMEN

Isolation rates of Haemophilus ducreyi from cases of chancroid are low. Experts recommend that isolation media be incubated at 33 to 35 degrees C, but the possible effect of this temperature range on the recovery of H. ducreyi has not been evaluated. We inoculated two sets of agar plates with material from genital ulcers and incubated one set at 33 degrees C and one at 35 degrees C; incubation at 33 degrees C identified 21% more cases than did incubation at 35 degrees C (109 versus 85 cases, respectively, of the 116 cases from which an isolation was made; P < 0.01).


Asunto(s)
Técnicas Bacteriológicas , Chancroide/diagnóstico , Haemophilus ducreyi/aislamiento & purificación , Agar , Chancroide/microbiología , Medios de Cultivo , Estudios de Evaluación como Asunto , Humanos , Temperatura
11.
Clin Infect Dis ; 20 Suppl 1: S39-46, 1995 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-7795108

RESUMEN

Since the 1989 Sexually Transmitted Diseases Treatment Guidelines were published by the Centers for Disease Control and Prevention, changes in the efficacy of the recommended and alternative regimens for the treatment of Haemophilus ducreyi infections have been described. Among recommended agents, erythromycin remains effective, and although a single dose of ceftriaxone appears to remain effective in the United States, limited data from Kenya have shown that this regimen has been associated with treatment failures. Of alternative treatment regimens, trimethoprim-sulfamethoxazole has been associated with widespread failure, but little work has been done to further evaluate the efficacy of the amoxicillin/clavulanic acid and ciprofloxacin regimens. Of the new antimicrobials, azithromycin has been very effective in the United States, but the efficacy of this drug elsewhere has not been thoroughly evaluated. Fleroxacin has been very effective in Kenya. Data from Africa indicate that patients who are infected with the human immunodeficiency virus do not respond to therapy as well as patients who are not, and patients who are uncircumcised may not respond as well to therapy as do patients who are circumcised.


Asunto(s)
Chancroide/tratamiento farmacológico , Antibacterianos/uso terapéutico , Humanos
12.
Clin Infect Dis ; 20 Suppl 1: S72-9, 1995 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-7795111

RESUMEN

We reviewed data on the treatment of bacterial vaginosis published from 1989 through 1992 (articles published after the 1989 publication of the Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines). This review suggests that oral metronidazole (500 mg twice daily for 7 days) is the preferred treatment for bacterial vaginosis. Other effective (but alternative) treatment regimens include single-dose metronidazole (2 g orally), 2% clindamycin vaginal cream (once daily for 7 days), 0.75% metronidazole vaginal gel (twice daily for 5 days), and oral clindamycin (300 mg twice daily for 7 days). Data do not support the practice of routine treatment of male sex partners of infected females. Treatment of bacterial vaginosis during pregnancy should focus on the elimination of symptoms; data on adverse pregnancy outcomes for women with bacterial vaginosis remain insufficient to recommend treatment of asymptomatic patients. Before performing surgical abortion, treatment of bacterial vaginosis (symptomatic or asymptomatic) should be considered to prevent pelvic inflammatory disease.


Asunto(s)
Vaginosis Bacteriana/tratamiento farmacológico , Administración Tópica , Femenino , Humanos , Masculino , Metronidazol/uso terapéutico , Embarazo , Complicaciones Infecciosas del Embarazo/tratamiento farmacológico , Parejas Sexuales , Procedimientos Quirúrgicos Operativos , Vaginosis Bacteriana/diagnóstico , Vaginosis Bacteriana/prevención & control
13.
Artículo en Inglés | MEDLINE | ID: mdl-7493197

RESUMEN

Economic evaluation (EE) answers the following simple question: "From which course of action do we get the most value for our money?" We ask this question because resources are always limited, i.e., we never have enough money to do all the things we would like to do. Three types of economic evaluations are used: cost-effectiveness analysis, cost-utility analysis, and cost-benefit analysis. Although all involve a monetary and outcome comparison of two or more courses of action, the methodologies and outcomes of each type vary, making each one particularly suited for specific and different indications. Although the performance of an EE may be complex, its concept is intuitively simple. Understanding the basic elements of economic analysis is more and more important to all health-care providers because health-care policy makers at all levels are increasingly using EE for allocating resources.


Asunto(s)
Análisis Costo-Beneficio , Síndrome de Inmunodeficiencia Adquirida/tratamiento farmacológico , Síndrome de Inmunodeficiencia Adquirida/economía , Antivirales/economía , Análisis Costo-Beneficio/economía , Técnicas de Apoyo para la Decisión , Árboles de Decisión , Humanos , Esperanza de Vida , Valor de la Vida
14.
Clin Infect Dis ; 17(3): 462-5, 1993 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-8218690

RESUMEN

To ascertain the prevalence of self-medication with antimicrobial agents among patients attending a clinic for treatment of sexually transmitted diseases (STDs), we administered a questionnaire to and collected a urine specimen for antimicrobial testing from 551 patients before treatment. We defined self-medication as an antimicrobial agent taken on the patient's own initiative by self-report during the week before the visit to the clinic or a positive urine assay for antimicrobial agents at the time of the clinic visit. We tested urine for the presence of antimicrobial agents by a disk diffusion method using Sarcina lutea as the test organism. A total of 75 (14%) of the 551 participants were self-medicators: 19 reported antimicrobial use and had a positive urine test, 27 reported antimicrobial use but had a negative urine test, and 29 denied antimicrobial use but had a positive urine test. Thus, 29 (60%) of the 48 patients with antimicrobial agents detected in their urine at the time of the clinic visit denied self-medication. Self-medicators acquired their antibiotics either from their medicine cabinet (44%) or from a family member or friend (56%). Self-medication was associated with self-report of prior use of unprescribed antimicrobial agents (P < .0001). We concluded that use of unprescribed antimicrobial agents (usually beta-lactam agents or tetracyclines) among STD clinic attendees in our study was common and that self-reporting was not a reliable method of screening for self-medicators.


Asunto(s)
Antibacterianos/uso terapéutico , Automedicación/estadística & datos numéricos , Enfermedades de Transmisión Sexual/tratamiento farmacológico , Adulto , Femenino , Humanos , Masculino , Prevalencia
15.
MMWR CDC Surveill Summ ; 41(3): 57-61, 1992 May 29.
Artículo en Inglés | MEDLINE | ID: mdl-1635549

RESUMEN

Chancroid, a bacterial sexually transmitted disease (STD) characterized by genital ulceration, has reemerged in the United States during the last decade. From 1950 to 1980, cases were infrequently reported. After an epidemic in California in 1981, however, the numbers of cases increased, peaking in 1987 at 5,035. Despite a subsequent decline in numbers of reported cases to 4,223 in 1990, new areas continue to report outbreaks. Interpreting chancroid surveillance data is difficult because confirmatory culture media are not commercially available. In addition, states may not require that unconfirmed or even confirmed cases be reported. To determine if chancroid is more widely distributed than surveillance figures indicate, CDC contacted STD clinics in 115 health departments, located in 32 states, the District of Columbia, and Puerto Rico--areas chosen because they had reported five or more cases of chancroid in any single year during 1986-1990--to determine if cases might be occurring but not reported. Only 16 of the 115 clinics had culture media available for Haemophilus ducreyi, and only nine had laboratory facilities complete enough to definitively diagnose chancroid, syphilis, or genital herpes, the most common STDs characterized by genital ulcers. Five or more clinically likely cases occurring in 1990 were identified in 24 states, seven more than surveillance figures indicated. Surveillance can be improved if a) states utilize the definitions for chancroid cases adopted for use in 1990 and b) microbiology laboratories utilize enhanced diagnostic methods.


Asunto(s)
Chancroide/epidemiología , Brotes de Enfermedades , District of Columbia/epidemiología , Femenino , Humanos , Masculino , Vigilancia de la Población , Puerto Rico/epidemiología , Estados Unidos/epidemiología
18.
Med Clin North Am ; 74(6): 1559-72, 1990 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-2246953

RESUMEN

The three major diseases characterized by genital ulcers--genital herpes, syphilis, and chancroid--are common, with genital herpes being most common in industrialized countries and chancroid being most common in developing countries. One fourth to one half of patients with genital ulcers have no diagnosed cause for their illness despite diagnostic efforts. The bulk of these cases is probably constituted by one of the three diseases for which diagnostic tests are falsely negative. There is accumulating evidence that genital ulcers facilitate the transmission of human immunodeficiency virus (HIV), and they may also be markers of high-risk behavior for acquisition of HIV. Appropriate therapy of patients with genital ulcers (as well as their sexual partners) depends on accurate diagnosis. Patients with genital ulcers, particularly those with syphilis or chancroid, should be encouraged to undergo testing for HIV infection.


Asunto(s)
Enfermedades de los Genitales Femeninos , Enfermedades de los Genitales Masculinos , Diagnóstico Diferencial , Femenino , Enfermedades de los Genitales Femeninos/diagnóstico , Enfermedades de los Genitales Femeninos/etiología , Enfermedades de los Genitales Femeninos/terapia , Enfermedades de los Genitales Masculinos/diagnóstico , Enfermedades de los Genitales Masculinos/etiología , Enfermedades de los Genitales Masculinos/terapia , Humanos , Masculino , Enfermedades de Transmisión Sexual/complicaciones , Enfermedades de Transmisión Sexual/diagnóstico , Enfermedades de Transmisión Sexual/terapia , Úlcera/diagnóstico , Úlcera/etiología , Úlcera/terapia
19.
Rev Infect Dis ; 12 Suppl 6: S580-9, 1990.
Artículo en Inglés | MEDLINE | ID: mdl-2201074

RESUMEN

Since recommendations for the treatment of chancroid were made in 1985, in vitro and in vivo data indicate that the two drugs recommended, erythromycin (500 mg four times a day for 7 days) and ceftriaxone (250 mg intramuscularly in a single dose), remain effective. The alternative therapies of trimethoprim-sulfamethoxazole (160/800 mg twice a day for 7 days) and amoxicillin-clavulanic acid (500/125 mg three times a day for 7 days) also appear to be effective, although there has been little experience with these drugs in the United States. Single-dose trimethoprim-sulfamethoxazole (640/3,200 mg) now lacks the efficacy of other regimens. The experience with ciprofloxacin (500 mg twice a day for 3 days) has been favorable, and other quinolones may prove useful. Concurrent infection with human immunodeficiency virus appears to result in an increased rate of failure of treatment for chancroid, and such cases may require more prolonged therapy.


Asunto(s)
Antiinfecciosos/uso terapéutico , Chancroide/tratamiento farmacológico , Haemophilus ducreyi/efectos de los fármacos , Antibacterianos , Antiinfecciosos/farmacología , Chancroide/complicaciones , Ensayos Clínicos como Asunto , Infecciones por VIH/complicaciones , Humanos , Recurrencia
20.
Sex Transm Dis ; 16(4): 184-9, 1989.
Artículo en Inglés | MEDLINE | ID: mdl-2595516

RESUMEN

We reviewed published and unpublished studies on seroprevalence of HIV antibody in persons attending sexually transmitted disease (STD) clinics in the United States from 1985 through 1987. We identified 23 studies from 16 states; nine studies determined risk factors for HIV. Overall, 899 (4.2%) of the 21,352 clinic attendees were seropositive; the seroprevalence rate was higher for men (5.9%) than for women (1.7%). Clinic seroprevalence ranged from 0.5% to 15.2% (median, 3.5%), reflecting in part the proportion of all attendees who were homosexual or bisexual, intravenous-drug users (IVDUs), or heterosexual partners of bisexual men or IVDUs (median proportion, 21.8% for the nine sites with this information). Most HIV-seropositive persons were at recognized risk (median for the same nine studies, 85.3%). Homosexual/bisexual men had the highest seroprevalence (median, 32.2%), followed by heterosexual IVDUs (median, 3.6%). Heterosexuals who denied intravenous-drug use had a median rate of 0.9%, which strongly correlated with rates in IVDUs in the same clinics (r = 0.88). We conclude many STD clinic attendees are infected with HIV. Because AIDS is an STD and seroprevalence has been associated with other STDs, STD clinics are important sites for HIV surveillance and risk-reduction education.


Asunto(s)
Seroprevalencia de VIH , Enfermedades Virales de Transmisión Sexual/transmisión , Adulto , Bisexualidad , Femenino , Homosexualidad , Humanos , Masculino , Factores de Riesgo , Abuso de Sustancias por Vía Intravenosa , Estados Unidos/epidemiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA